WO2011142731A3 - Formulations comprising a third generation cephalosporin and clavulanic acid - Google Patents

Formulations comprising a third generation cephalosporin and clavulanic acid Download PDF

Info

Publication number
WO2011142731A3
WO2011142731A3 PCT/TR2011/000124 TR2011000124W WO2011142731A3 WO 2011142731 A3 WO2011142731 A3 WO 2011142731A3 TR 2011000124 W TR2011000124 W TR 2011000124W WO 2011142731 A3 WO2011142731 A3 WO 2011142731A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
clavulanic acid
generation cephalosporin
cephalosporin
generation
Prior art date
Application number
PCT/TR2011/000124
Other languages
French (fr)
Other versions
WO2011142731A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11743665A priority Critical patent/EP2568959A2/en
Publication of WO2011142731A2 publication Critical patent/WO2011142731A2/en
Publication of WO2011142731A3 publication Critical patent/WO2011142731A3/en
Priority to US13/668,922 priority patent/US20130129791A1/en
Priority to US14/309,273 priority patent/US20150140111A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid and/or derivatives thereof as the active agent.
PCT/TR2011/000124 2010-05-04 2011-05-13 Formulations comprising a third generation cephalosporin and clavulanic acid WO2011142731A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP11743665A EP2568959A2 (en) 2010-05-14 2011-05-13 Formulations comprising a third generation cephalosporin and clavulanic acid
US13/668,922 US20130129791A1 (en) 2010-05-04 2012-11-05 Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
US14/309,273 US20150140111A1 (en) 2010-05-04 2014-06-19 Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/03854 2010-05-14
TR201003854 2010-05-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000127 Continuation-In-Part WO2011139252A2 (en) 2010-05-04 2011-05-02 Efervescent formulations comprising cefdinir

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000131 Continuation-In-Part WO2011139254A2 (en) 2010-05-04 2011-05-02 Pharmaceutical formulations compising cefuroxime axetil
US13/668,922 Continuation-In-Part US20130129791A1 (en) 2010-05-04 2012-11-05 Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof

Publications (2)

Publication Number Publication Date
WO2011142731A2 WO2011142731A2 (en) 2011-11-17
WO2011142731A3 true WO2011142731A3 (en) 2012-03-08

Family

ID=44487006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000124 WO2011142731A2 (en) 2010-05-04 2011-05-13 Formulations comprising a third generation cephalosporin and clavulanic acid

Country Status (2)

Country Link
EP (1) EP2568959A2 (en)
WO (1) WO2011142731A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2800570A1 (en) * 2012-01-03 2014-11-12 Zoetis LLC A method for treating lyme disease
CN103142506B (en) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 Cefpodoxime proxetil granules and preparation method thereof
KR101420315B1 (en) 2014-03-19 2014-07-17 남봉길 Pharmaceutical liquid composition
US20170252351A1 (en) * 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions
RU2018105869A (en) 2015-08-17 2019-09-19 Ферринг Б.В. LIQUID COMPOSITIONS CONTAINING PICOSULFATE AND MAGNESIUM CITRATE
WO2018013870A1 (en) 2016-07-14 2018-01-18 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
CN115581700A (en) * 2021-03-22 2023-01-10 湘北威尔曼制药股份有限公司 Pharmaceutical composition containing cefotaxime sulbactam or cefotaxime tazobactam with stable quality and high antibacterial activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1706389A (en) * 2005-05-26 2005-12-14 济南平志医药科技有限公司 Effervescent cefdinir prepn and its prepn process
US20070134325A1 (en) * 1996-02-29 2007-06-14 Astellas Pharma Inc. Beta-lactam antibiotic-containing tablet and production thereof
CN101352424A (en) * 2008-09-16 2009-01-28 天津市中央药业有限公司 Cefdinir dispersible tablet and preparation method thereof
US20090155387A1 (en) * 2006-08-25 2009-06-18 Hesheng Zhang Stable pharmaceutical composition comprising beta-lactam antibiotic and ion-chelating agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705562D0 (en) 1987-03-10 1987-04-15 Cardiff Energy & Resources Whey processing
GB9114950D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Pharmaceutical formulation
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134325A1 (en) * 1996-02-29 2007-06-14 Astellas Pharma Inc. Beta-lactam antibiotic-containing tablet and production thereof
CN1706389A (en) * 2005-05-26 2005-12-14 济南平志医药科技有限公司 Effervescent cefdinir prepn and its prepn process
US20090155387A1 (en) * 2006-08-25 2009-06-18 Hesheng Zhang Stable pharmaceutical composition comprising beta-lactam antibiotic and ion-chelating agent
CN101352424A (en) * 2008-09-16 2009-01-28 天津市中央药业有限公司 Cefdinir dispersible tablet and preparation method thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2009, GANDHI SANTOSH V ET AL: "Simultaneous spectrophotometric determination of Cefpodoxime proxetil and Potassium clavulanate.", XP002666412, Database accession no. NLM21268556 *
DATABASE WPI Week 200630, Derwent World Patents Index; AN 2006-285271, XP002620814 *
DATABASE WPI Week 200925, Derwent World Patents Index; AN 2009-F19584, XP002620815 *
LIVERMORE D M ET AL: "Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers", CLINICAL MICROBIOLOGY AND INFECTION : THE OFFICIAL PUBLICATION OF THE EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES JAN 2008 LNKD- PUBMED:18154546,, vol. 14 Suppl 1, 1 January 2008 (2008-01-01), pages 189 - 193, XP002637026 *
PRAKASH V. ET AL.: "Oral and parenteral therapeutic options for outpatient urinary infections aused by Enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 53, no. 3, 5 January 2009 (2009-01-05), pages 1278 - 1280, XP002628190, DOI: 10.1128/AAC.01519-08 *
See also references of EP2568959A2 *

Also Published As

Publication number Publication date
EP2568959A2 (en) 2013-03-20
WO2011142731A2 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
IL222548A (en) Hydroxamic acid derivatives and pharmaceutical compositions and antimicrobial agents comprising the same
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011093823A3 (en) Effervescent formulations comprising cefaclor and clavulanic acid
WO2011012816A3 (en) Pharmaceutical formulation
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
IL226270A0 (en) Hydroxamic acid derivatives, compositions comprising the same and uses thereof
WO2012009723A8 (en) C-met modulator pharmaceutical compositions
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
WO2012048176A3 (en) Attachment and retention formulations for biologically active organic compounds
WO2010021607A3 (en) Pharmaceutical formulation
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
WO2011152809A3 (en) Effervescent formulations comprising cephalosporin and clavulanic acid
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
IL226003A0 (en) Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2011135580A3 (en) Pharmaceutical compositions of sirolimus
WO2012064302A3 (en) Improved montelukast formulations
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
WO2011103920A3 (en) Pharmaceutical or neutraceutical formulation
WO2011139253A3 (en) Pharmaceutical compositions comprising ceftibuten
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
PH12014501384A1 (en) Antibiotic formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743665

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011743665

Country of ref document: EP